Dr. Michael Wacker

About

Michael is an experienced life science entrepreneur who joined Biomed in 2019. He has successfully built up various start-up companies and coaches start-ups in Switzerland for Innosuisse. Previously he was chairman of Inositec (acquired by Vifor Pharma) and board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015. Michael co-founded GlycoVaxyn in 2004 as a Spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a M.Sc. in biochemistry and completed his Ph.D. and post-doctoral fellowship in microbiology at ETHZ. He is the author of several publications in international scientific journals, including Science and PNAS, as well as inventor of various patent applications.